Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34607757http://www.w3.org/2000/01/rdf-schema#comment"

Background

CDK4/6 inhibitors have been used to treat hormone receptor-positive HER2-negative advanced breast cancer. Their benefit in HER2-positive breast cancer has not been determined yet. In this study, we investigated the effects of HER2 on CDK4/6 activity by assessing the level of downstream phosphorylated retinoblastoma protein (pRb) in HER2-positive breast cancer (HER2 positivity is defined by immunohistochemical study or FISH, regardless of ER status) to determine if these cases may be responsive to CDK4/6 inhibitors.

Materials and methods

One hundred and thirty cases of breast biopsies with invasive carcinoma were collected, including 77 cases of HER2+ (39 cases of ER +PR±HER2+ and 38 cases of ER-PR-HER2+) and 53 cases of HER2-(ER-PR-HER2-) breast cancer. Immunohistochemical study of pRb was performed and the pRb level was assessed by H-score (intensity x percentage of positive cells).

Results

The pRb H-score ranges from 3 to 270. The average H-scores for the ER-PR-HER2+, ER+PR±HER2+ and ER-PR-HER2-groups are 115.8 ± 75.8, 93.1 ± 68.6 and 63.1 ± 65.6, respectively. By comparison, HER2+ cases have significantly higher pRb levels than HER2-cases (P = .001). Among HER2+ cases, there was a trend of positive correlation between the HER2 gene copy number, and the pRb level although not statistically significant (r = 0.192, 95% CI, [-0.033, 0.399], P = .09).

Conclusion

In breast cancer, HER2 positivity leads to significantly higher levels of CDK4/6 activity as reflexed by pRb. Breast cancer that is positive for HER2 may respond to CDK4/6 inhibitors and pRb may potentially be used as a biomarker to predict the responsiveness."xsd:string
http://purl.uniprot.org/citations/34607757http://purl.org/dc/terms/identifier"doi:10.1016/j.clbc.2021.08.007"xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/author"Cui X."xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/author"Sinclair W.D."xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/name"Clin Breast Cancer"xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/pages"e278-e285"xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/title"The Effects of HER2 on CDK4/6 Activity in Breast Cancer."xsd:string
http://purl.uniprot.org/citations/34607757http://purl.uniprot.org/core/volume"22"xsd:string
http://purl.uniprot.org/citations/34607757http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/34607757
http://purl.uniprot.org/citations/34607757http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/34607757
http://purl.uniprot.org/uniprot/#_A0A8A0Y2Q6-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_A0A0R9RWK2-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_E2I6F8-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_B4DTR1-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_B4DLA2-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_J3QLU9-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_F5H1T4-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_P04626-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_Q00534-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_Q4H1F2-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_Q4H1F1-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_Q9NP09-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
http://purl.uniprot.org/uniprot/#_Q9UK79-mappedCitation-34607757http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34607757
▶